Is Apogee Therapeutics Inc. ( APGE ) Outperforming Other Medical Stocks This Year?
Here is how Apogee Therapeutics Inc. (APGE) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026. APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head ...
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing ...
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics to Participate in Upcoming Conferences - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( NASDAQ:APGE ) , today announced that members of management will participate at the following investor conferences.
Wall Street Analysts Believe Apogee Therapeutics Inc. ( APGE ) Could Rally 69.3%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 69.3% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Does Apogee Therapeutics Inc. ( APGE ) Have the Potential to Rally 72.52% as Wall Street Analysts Expect?
The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million
SAN FRANCISCO and BOSTON, Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( NASDAQ:APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Why Apogee Therapeutics Stock Triumphed on Thursday
The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - AZZ ( NYSE:AZZ ) , Apogee Therapeutics ( NASDAQ:APGE )
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday. Shares of Helen of Troy Ltd ( NASDAQ:HELE ) fell sharply in today's pre-market trading following second-quarter results.
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics ( NASDAQ:APGE ) , Ambow Education Holding ( AMEX:AMBO )
Shares of Richardson Electronics, Ltd. ( NASDAQ:RELL ) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Richardson Electronics reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 1 ...
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( NASDAQ:APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc. ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology ( EADV ) 2025 Congress
SAN FRANCISCO and BOSTON, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology ( I&I ) markets, today ...
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
SAN FRANCISCO and BOSTON, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m.
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis ...
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. ( APGE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Gold Falls 1%; ProKidney Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday. The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39. Energy shares jumped by 2.1% on Tuesday.
Dow Dips 1%; Mustang Bio Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Artelo Biosciences ( NASDAQ:ARTL )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday. The Dow traded down 1% to 44,379.69 while the NASDAQ declined 0.85% to 20,426.99. The S&P 500 also fell, dropping, 0.39% to 6,255.16. Industrials shares jumped by 0.1% on Monday.
Top 2 Health Care Stocks That May Plunge This Month - Apogee Therapeutics ( NASDAQ:APGE ) , Phibro Animal Health ( NASDAQ:PAHC )
As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial - Apogee Therapeutics ( NASDAQ:APGE )
APG777 cut eczema severity by 71% at Week 16 vs. 33.8% for placebo; 66.9% reached EASI-75. Itch severity reduced by 50.7% within one week; APG777 was well tolerated with no safety concerns raised. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics ( NASDAQ:APGE ) , Apogee Enterprises ( NASDAQ:APOG )
Shares of Apogee Therapeutics, Inc. APGE rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week ...
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, July 06, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for the ...
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET Webcast to be held Monday, July 7th at 8:00 a.m. ET ...
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. ( APGE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, May 29, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Wall Street Analysts Think Apogee Therapeutics Inc. ( APGE ) Could Surge 132.72%: Read This Before Placing a Bet
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Apogee Therapeutics ( NASDAQ:APGE )
APG808 cut FeNO by 53% at week 12, with sustained 50% reduction, showing anti-inflammatory effect. No Grade 3 or severe adverse events; most common side effects included headache and mild injection reactions. Don't miss this list of 3 high-yield stocks-including one delivering over 10%-built for ...
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling ...
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of ...
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - Apogee Therapeutics ( NASDAQ:APGE )
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease ...
Wall Street Analysts Believe Apogee Therapeutics Inc. ( APGE ) Could Rally 134%: Here's is How to Trade
The mean of analysts' price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
SAN FRANCISCO and BOSTON, May 01, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T.
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - Apogee Therapeutics ( NASDAQ:APGE )
APG990's Phase 1 trial showed a 60-day half-life, supporting three- and six-month dosing. Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades ...
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule. topline Part A 16-week data expected ...
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 ( APG777 + APG990 )
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately ...
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET Webcast to be held Monday, March 3rd at 8:30 a.m. ET ...
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Conference Date: Tuesday, March 4, 2025 Time: 2:30 p.m. ET
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
SAN FRANCISCO and BOSTON, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled ...
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of ...
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - Apogee Therapeutics ( NASDAQ:APGE )
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Apogee Therapeutics ( NASDAQ:APGE )
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., APGE, a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for ...
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 ( GLOBE NEWSWIRE ) -- Apogee Therapeutics, Inc., ( Nasdaq: APGE ) , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, ...
